Literature DB >> 17332938

Leukemia inhibitory factor functions as a growth factor in pancreas carcinoma cells: Involvement of regulation of LIF and its receptor expression.

Hidenobu Kamohara1, Michio Ogawa, Takatoshi Ishiko, Kiyoshi Sakamoto, Hideo Baba.   

Abstract

Leukemia inhibitory factor (LIF) is a pleiotrophic cytokine, which plays an important role in inducing cancer cachexia. We have previously reported that LIF promotes cell proliferation in some human carcinoma cells through c-fos, jun-B and cyclin-E expression. In the present study, we analyzed the regulation of LIF and its receptor (LIFR) expression in pancreatic carcinoma cells. Seven pancreatic carcinoma cells expressed constitutively LIF and its heterodimer receptor (LIFR and gp130) mRNA in RPMI-1640 medium without FBS. The amount of LIF immunoreactive protein was 132.5+/-52 pg/10(6) cells in culture supernatants without FBS. Pro-inflammatory cytokines, such as TNF-alpha, IL-1beta, IL-6, IL-8, or LIF, enhanced the expression of LIF mRNA in Hs-700T and Hs-766T cells. Addition of LIF significantly induced cell proliferation of Hs700T in 13 days LIF dose-dependently. However, anti-LIF IgG failed to suppress cell proliferation in Hs-700T cells. LIF acted as a paracrine growth factor in Hs-700T cells, which expressed low amount of LIF without stimuli. Cellular signal transductions by LIF was down-regulated by inhibitors of protein kinase C (PKC), protein tyrosine kinase (PTK), and Ca/Calmodulin. LIF induced phosphorylation of STAT3. Moreover, exogenous LIF upregulated the expression of LIFR mRNA. Antisense LIFR oligonucleotide significantly suppressed cell growth in the presence of LIF in Hs-700T cells. These results suggest that cytokine network might alter the expression and responsiveness to LIF in tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17332938

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  27 in total

1.  EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.

Authors:  Suryavathi Viswanadhapalli; Yiliao Luo; Gangadhara R Sareddy; Bindu Santhamma; Mei Zhou; Mengxing Li; Shihong Ma; Rajni Sonavane; Uday P Pratap; Kristin A Altwegg; Xiaonan Li; Annabel Chang; Alejandra Chávez-Riveros; Kalarickal V Dileep; Kam Y J Zhang; Xinlei Pan; Ramachandran Murali; Marek Bajda; Ganesh V Raj; Andrew J Brenner; Vijaya Manthati; Manjeet K Rao; Rajeshwar R Tekmal; Hareesh B Nair; Klaus J Nickisch; Ratna K Vadlamudi
Journal:  Mol Cancer Ther       Date:  2019-05-29       Impact factor: 6.261

2.  Epigenetic up-regulation of leukemia inhibitory factor (LIF) gene during the progression to breast cancer.

Authors:  Jung Eun Shin; Su Hyung Park; Yeun Kyu Jang
Journal:  Mol Cells       Date:  2010-12-03       Impact factor: 5.034

3.  Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer.

Authors:  Sharon R Pine; Leah E Mechanic; Lindsey Enewold; Anil K Chaturvedi; Hormuzd A Katki; Yun-Ling Zheng; Elise D Bowman; Eric A Engels; Neil E Caporaso; Curtis C Harris
Journal:  J Natl Cancer Inst       Date:  2011-06-17       Impact factor: 13.506

4.  Heavy LIFting: tumor promotion and radioresistance in NPC.

Authors:  Micah Luftig
Journal:  J Clin Invest       Date:  2013-11-25       Impact factor: 14.808

5.  Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance.

Authors:  Shu-Chen Liu; Ngan-Ming Tsang; Wen-Che Chiang; Kai-Ping Chang; Chuen Hsueh; Ying Liang; Jyh-Lyh Juang; Kai-Ping N Chow; Yu-Sun Chang
Journal:  J Clin Invest       Date:  2013-11-25       Impact factor: 14.808

Review 6.  The emerging role of leukemia inhibitory factor in cancer and therapy.

Authors:  Cen Zhang; Juan Liu; Jianming Wang; Wenwei Hu; Zhaohui Feng
Journal:  Pharmacol Ther       Date:  2020-11-28       Impact factor: 12.310

7.  Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma.

Authors:  Arokia Priyanka Vaz; Shonali Deb; Satyanarayana Rachagani; Parama Dey; Sakthivel Muniyan; Imayavaramban Lakshmanan; Saswati Karmakar; Lynette Smith; Sonny Johansson; Subodh Lele; Michel Ouellette; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Oncotarget       Date:  2016-01-19

8.  Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.

Authors:  Winnie S Liang; David W Craig; John Carpten; Mitesh J Borad; Michael J Demeure; Glen J Weiss; Tyler Izatt; Shripad Sinari; Alexis Christoforides; Jessica Aldrich; Ahmet Kurdoglu; Michael Barrett; Lori Phillips; Hollie Benson; Waibhav Tembe; Esteban Braggio; Jeffrey A Kiefer; Christophe Legendre; Richard Posner; Galen H Hostetter; Angela Baker; Jan B Egan; Haiyong Han; Douglas Lake; Edward C Stites; Ramesh K Ramanathan; Rafael Fonseca; A Keith Stewart; Daniel Von Hoff
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

9.  Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.

Authors:  J Kumar; F W Fraser; C Riley; N Ahmed; D R McCulloch; A C Ward
Journal:  Br J Cancer       Date:  2013-11-12       Impact factor: 7.640

10.  LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway.

Authors:  Xiaoyan Li; Qifeng Yang; Haiyang Yu; Lihua Wu; Yuhan Zhao; Cen Zhang; Xuetian Yue; Zhen Liu; Hao Wu; Bruce G Haffty; Zhaohui Feng; Wenwei Hu
Journal:  Oncotarget       Date:  2014-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.